Matthias Müllenbeck: What if we paid doctors to keep people healthy?
マティアス・ミュレンベック: 医師の報酬を健康維持を基準に支払うとしたら?
As the Biopharma director for licensing and business development at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck is responsible for leading strategic partnering initiatives in the field of oncology and immuno-oncology. Full bio
Double-click the English transcript below to play the video.
fell off the evening before.
外れてしまいました
I'm sitting in a dentist's chair.
座っていました
so that I can get rid of my pain,
痛みを取り除くのではなく
of a titanium implant surgery.
利点を売り込みました
a damaged tooth
外れた歯の代わりとなる人工歯を
may add up to 10,000 US dollars.
1万ドルにのぼることもあります
that could be earned with me
私の健康でしょうか
for my dentist?
治療して稼げる金額でしょうか?
wasn't an isolated case.
例外ではありませんでした
estimated that in the United States,
全ての外科手術の30%までもが―
surgical procedures --
and pacemaker implantations,
options had not been fully exploited
in other countries,
if you go to a doctor in the US,
アメリカで医者にかかると
to be subjected to a surgical intervention
an immediate need for it.
to run such unnecessary procedures?
不要な処置の勧めに急ぐのは何故でしょう?
health care systems themselves
certain procedures or treatments.
適用又は不適用の判断を迫るからでしょう
reimburse practitioners
医療提供者の報酬が
of treatments performed,
診察費を払う制度となっており
that tempts some practitioners
一部の医療提供者は
surgical treatments
手術による処置を行って
other treatment options.
検討しないのかもしれません
started to implement
実施し始めていますが
health care systems' architecture
既存の医療制度の仕組みの中には
of a disease in the first place
特に効果的なものに限定することに
applied to a patient
system's architecture --
必要ではないでしょうか
of the incentive structure.
for keeping their customers healthy
医療提供者に報酬を支払う医療制度で
once people are already sick.
ほぼ支払いをしない制度に代わるものです
that largely cares for the sick,
今のシステムから
people once they have become sick
before they get sick.
発想を転換することです
of all those involved --
to pharmaceutical and medical companies --
医療機器会社といった全ての者の
ultimately sells:
変わることが考えられます
reimburse practitioners
報酬ではなく
performed on a patient
individual is kept healthy
病気を発症せずに過ごせた日に対し
to an insurance company
「健康費」を支払います
is kept healthy
of acute medical intervention.
日払いの勘定です
any further monetary compensation
医学的処置に対する
to treat the disease of that individual,
for every evidence-based treatment option
患者の健康を回復するのに必要な
支払いを義務づけます
will be paid again.
their customers healthy,
any unnecessary medical interventions
that eventually become sick.
避けることを奨励します
to treat the sick will be,
for all parties being involved
促進することに関わった全ての人たちの
structure shifts, now,
health care system
and singular treatment options,
何が有益かという
to stay healthy and live long.
to share their health data
understands early enough
to their health is needed.
早期に判断できます
cardiometabolic profiling
心代謝系のプロファイリングや
and general practitioners,
and their physical activity --
individual high-risk disease.
data analysis
of sensor technologies
of the individual health status possible.
既に始まっています
by devices like this
パラメーターを測ることや
tumor DNA in your bloodstream
for such monitoring technologies.
2つの例です
in certain oncological diseases
大きな課題の1つが
is diagnosed too late
that could potentially have cured them
医薬品と処置は
been detected earlier.
based on a few milliliters of blood,
数mlの血液サンプルだけで
of circulating tumor DNA
detection can have
発見することの影響は
for non-small cell lung cancer
which is early, is 49 percent.
49%です
at stage four, which is late,
ステージ4で診断されると
to prevent a large number of deaths
簡単に多くの命が救える―
for circulating tumor DNA
a manageable disease,
処置可能な病気に位置づけられます
can likely be increased.
had a single chronic disease,
慢性疾患を1つ抱えており
of the $3 trillion US health care budget
such chronic diseases.
治療に充てられています
to reduce this 86 percent,
この86%という数値を減らせるとすれば
not reacted and changed already?
それに対応し変化しないのでしょうか?
is a sick care system
that focuses on prevention
真の意味の医療制度に変えるには
in the system to change.
見方を改めることが求められます
to shift budgets and policies
奨励の仕組みを考え直すための
予算や政策を転換させる―
and non-financial incentives.
a regulatory framework
of personal health data
stringent and sensible.
必要となります
pharmaceutical and medical companies
薬品と医療機器会社が
and, most important,
加えて 最も重要なこととして
the willingness and motivation
個人の意志と動機です
in a sustained way,
持続させようとか
the health data on a constant basis.
継続することと併せて必要です
一夜のうちには起こりません
within the health care industry today
もう一度注目して
維持しようとすることで
more diseases in the first place
予防できるだけではなく
the onset of certain preventable diseases
and healthier lives for more people.
長生きの人生につながるでしょう
that we need to initiate that change
展望と―
ABOUT THE SPEAKER
Matthias Müllenbeck - Business developerAs the Biopharma director for licensing and business development at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck is responsible for leading strategic partnering initiatives in the field of oncology and immuno-oncology.
Why you should listen
Throughout his career in various roles at Merck KGaA, Darmstadt, Germany, Matthias Müllenbeck worked on strategic asset, technology and diagnostic-licensing deals and on bringing to market innovative chemical products. He holds a PhD in immunology from the Humboldt University in Berlin and has worked at the Max-Planck Institute for infection biology in Berlin, at Bayer, and at the Albert-Schweizer Hospital in Lambarané, Gabon.
Matthias Müllenbeck | Speaker | TED.com